Benitec Biopharma
BNTC
4 hedge funds and large institutions have $198K invested in Benitec Biopharma in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
71% less capital invested
Capital invested by funds: $690K → $198K (-$492K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$59.3K |
| 2 |
JP Morgan Chase
New York
|
+$468 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$443K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$6K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.29K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $113K | +$59.3K | +507 | +82% |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $85K | -$443K | -3,792 | -82% |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$6K | -42 | Closed |
|
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1.29K | -11 | -79% |
|
|
5
JP Morgan Chase
New York
| – | +$468 | +4 | New |
|
BNTC Hedge Fund Activity: Q1 2020 in Review
4 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2020, worth a combined $198K — down 71% from $690K a quarter earlier.
Fund positioning in BNTC was balanced in Q1 2020: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $59.3K. The largest seller was Sabby Management, cutting an estimated $443K.
- 4 institutional investors held Benitec Biopharma (BNTC) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $198K of Benitec Biopharma stock for Q1 2020, down 71% quarter-over-quarter.
- 1 fund opened new Benitec Biopharma positions in Q1 2020 and 1 closed out, a net change of 0 holders.
- The largest Benitec Biopharma buyer in Q1 2020 was Morgan Stanley, an estimated $59.3K added.
- The largest Benitec Biopharma seller in Q1 2020 was Sabby Management, an estimated $443K sold.
Based on aggregated 13F filings for Q1 2020.